Predicting chemo response in pancreatic cancer
Part of Cancer clinical trials.
This study looks at blood samples to see if we can predict how well pancreatic cancer responds to chemotherapy before surgery. It aims to help doctors choose the best treatment for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that started in the ducts (pancreatic ductal adenocarcinoma).
- You received chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) before surgery.
- You had a blood sample taken before starting chemotherapy.
- You had surgery to remove the cancer (with clean or nearly clean margins).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether people with pancreatic cancer should get standard chemo or a chemo plan guided by a tumor gene/RNA test after surgery. It aims to see if the right chemo choice for your tumor biology can improve outcomes after your tumor is removed.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial tests a personalized approach by growing a miniature model of your tumor from a tissue sample. The goal is to see if this model can predict which chemotherapy will work best for you before you start treatment.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.